Cas:40657-29-2 1,1,1-trifluoro-4,4-diethoxy-3-buten-2-one manufacturer & supplier

Chemical Name:1,1,1-trifluoro-4,4-diethoxy-3-buten-2-one

CAS.NO:40657-29-2

Synonyms:4,4-diethoxy-1,1,1-trifluoro-3-buten-2-one;4,4-diethoxy-1,1,1-trifluorobut-3-en-2-one;Trifluoroacetylketene diethyl ketal;4,4-diethoxy-1,1,1-trifluoro-but-3-en-2-one;trifluoroacetyl-ketene diethyl acetal;trifluoracetylketene diethylacetal

Molecular Formula:C₈H₁₁F₃O₃

Molecular Weight:212.16600

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:35.53000

Exact Mass:212.06600

LogP:2.03220

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4,4-diethoxy-1,1,1-trifluoro-3-buten-2-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,trifluoracetylketene diethylacetal physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4,4-diethoxy-1,1,1-trifluoro-but-3-en-2-one Use and application,trifluoracetylketene diethylacetal technical grade,usp/ep/jp grade.

Related News: Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. 1,1,1-trifluoro-4,4-diethoxy-3-buten-2-one manufacturer Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. 1,1,1-trifluoro-4,4-diethoxy-3-buten-2-one supplier China has granted conditional approval to its first self-developed treatment for Alzheimer��s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug. 1,1,1-trifluoro-4,4-diethoxy-3-buten-2-one vendor The New York Times said that the batches being discarded amount to around 60 million doses, citing people familiar with the matter. 1,1,1-trifluoro-4,4-diethoxy-3-buten-2-one factory The New York Times said that the batches being discarded amount to around 60 million doses, citing people familiar with the matter.